Cell And Gene Therapy Product Portfolio

Lonza provides a comprehensive portfolio of products, technologies, and CDMO services designed to support cell and gene therapy (CGT) developers from early discovery through commercial manufacturing.

With a global network of GMP-compliant facilities and decades of industry expertise, Lonza helps accelerate development timelines, streamline manufacturing processes, and support regulatory readiness. Its portfolio includes ethically sourced primary and stem cells, specialized media and reagents, scalable electroporation technologies, rapid microbial detection systems, and advanced endotoxin testing solutions.

In addition, Lonza offers end-to-end development and manufacturing services, enabling researchers and biopharmaceutical companies to advance innovative therapies more efficiently and bring transformative treatments to patients worldwide.